Summary:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).
- Male or female, 18 to 60 years of age, inclusive.
- Current diagnosis of schizophrenia according to DSM-5 criteria as determined by the modified Structured Clinical Interview for DSM-5 (modified SCID-5).
- Diagnosis of schizophrenia for a minimum of 1 year before Visit 1.
- Current psychotic episode < 4 weeks duration at Visit 1.
- PANSS total score ≥ 70 and ≤ 120 at Visit 1 and Visit 2.
- Rating of at least 4 (moderate) on at least two of the following four PANSS positive symptoms: delusions (P1), hallucinatory behavior (P3), conceptual disorganization (P2), suspiciousness/persecution (P6) at Visit 1 and Visit 2.
- Patient must identify a caregiver who provides consent to participate in the study.
- In the opinion of the Investigator, the patient has significant risk for suicidal behavior during the course of his/her participation in the study.
Qualified Participants May Receive:
Monetary compensation for participation.